Abbott has secured U.S. FDA approval for its TactiFlex™ Duo Ablation Catheter, marking another important step in
the company’s strategy to regain share and accelerate growth in the competitive electrophysiology (EP) market.
The device brings pulsed field ablation (PFA) and radiofrequency (RF) energy into a single catheter, allowing physicians to switch between energy modalities and tailor treatment based on individual patient and procedural needs.
Why this matters
• Dual-energy flexibility: TactiFlex Duo combines the tissue selectivity of PFA with the established capabilities of RF ablation, giving electrophysiologists greater procedural flexibility.
• Clinical validation: Recent FlexPulse IDE study results demonstrated the catheter’s safety and effectiveness in patients with paroxysmal atrial fibrillation (AFib).
• Expanding PFA portfolio: The approval complements Abbott’s Volt PFA catheter, introduced in the U.S. earlier this year, creating a broader platform for competing across the rapidly expanding PFA segment.
• Competitive implications: PFA adoption has accelerated significantly, intensifying competition among Abbott, Boston Scientific, Medtronic and Johnson & Johnson as companies invest in next-generation cardiac ablation technologies.
The strategic perspective
TactiFlex Duo is more than another catheter launch. Its ability to provide two ablation modalities through one devicecould become an important differentiator as physicians increasingly seek flexibility, efficiency and improved safety in AFib procedures.
For Abbott, the combination of Volt + TactiFlex Duo creates a stronger electrophysiology portfolio at a critical point in the PFA adoption curve. CEO Robert Ford has indicated that the two technologies are expected to help Abbott regain EP market share and deliver growth above the broader market.
Abbott plans to begin TactiFlex Duo procedures across the U.S. in the coming weeks.
#Abbott #TactiFlexDuo #AtrialFibrillation #AFib #Electrophysiology #PulsedFieldAblation #PFA #CardiacAblation #MedTech #MedicalDevices #Cardiology #BostonScientific #Medtronic #JohnsonAndJohnson #HealthcareInnovation